摘要
OBJECTIVE@#To quantify phytochemicals using liquid chromatography and mass spectroscopy (LCMS) analysis and explore the therapeutic effect of Aesculus hippocastanum L. (AH) seeds ethanolic extract against gastric ulcers in rats.@*METHODS@#Preliminary phytochemical testing and LCMS analysis were performed according to standard methods. For treatment, the animals were divided into 7 groups including normal control, ulcer control, self-healing, AH seeds low and high doses, ranitidine and per se groups. Rats were orally administered with 10 mg/kg of indomethacin, excluding the normal control group (which received 1% carboxy methyl cellulose) and the per se group (received 200 mg/kg AH seeds extract). The test group rats were then given 2 doses of AH seeds extract (100 and 200 mg/kg, respectively), while the standard group was given ranitidine (50 mg/kg). On the 11th day, rats in all groups were sacrificed, and their stomach was isolated to calculate the ulcer index, and other parameters such as blood prostaglandin (PGE2), tissue superoxide dismutase (SOD), catalase (CAT), malonyldialdehyde (MDA), and glutathione (GSH). All isolated stomach tissues were analyzed for histopathological findings.@*RESULTS@#The phytochemical examination shows that the AH seeds contain alkaloids, flavonoids, saponins, phenolic components, and glycosides. LCMS analysis confirms the presence of quercetin and rutin. The AH seeds extract showed significant improvement in gastric mucosa conditions after indomethacin-induced gastric lesions (P<0.01). Further marked improvement in blood PGE2 and antioxidant enzymes, SOD, CAT, MDA and GSH, were observed compared with self-healing and untreated ulcer-induced groups (P<0.01). Histopathology results confirmed that AH seeds extract improved the mucosal layer and gastric epithelial membrane in treated groups compared to untreated ulcer-induced groups.@*CONCLUSIONS@#LCMS report confirms the presence of quercetin and rutin in AH seeds ethanolic extract. The therapeutic effect of AH seeds extract against indomethacin-induced ulcer in rat model indicated the regenerated membrane integrity, with improved cellular functions and mucus thickness. Further, improved antioxidant enzyme level would help to reduce PGE2 biosynthesis.
Subject(s)
Rats , Animals , Stomach Ulcer/pathology , Antioxidants/therapeutic use , Ranitidine/adverse effects , Aesculus , Ulcer/drug therapy , Quercetin , Plant Extracts/chemistry , Indomethacin/therapeutic use , Glutathione , Superoxide Dismutase , Rutin/adverse effects , Prostaglandins/adverse effects , Phytochemicals/therapeutic use摘要
ABSTRACT Objective: To characterize the number and methods of closure of Persistent Ductus Arteriosus (PDA) over a span of 16 years in a third level maternity hospital. Methods: Retrospective study of neonates born between January 2003 and Deccember 2018, who underwent ductus arteriosus closure by pharmacological, surgical and/or transcatheter methods. Gestational age, birth weight, number and methods of closures per year were evaluated. The success rate of the pharmacologic method was calculated, as well as the mortality rate. The association between mortality and birthweight, treatment used and treatment failure was explored. Results: There were 47,198 births, 5,156 were preterm, 325 presented PDA and 106 were eligible for closure (median gestational age - 27 weeks, birthweight <1000 g - 61%). Frequency of PDA closure decreased during the study period, especially starting in 2010. Success rate with pharmacologic treatment was 62% after the first cycle and 74% after the second. After drug failure, 12 underwent surgical ligation and two underwent transcatheter closure. Exclusive surgical ligation was indicated in four infants. Ibuprofen replaced indomethacin in 2010, and acetaminophen was used in three infants. Among the 106 infants, hospital mortality was 12% and it was associated with birthweight <1000 g (13/65 <1000 vs. 0/41 >1000 g; p=0.002) and with failure in the first pharmacologic treatment cycle (13/27 with failure, vs. 0/75 without failure; p<0.001). Conclusions: The national consensus published in 2010 for the diagnosis and treatment of PDA in preterm infants led to a decrease in the indication for closure. Pharmacological closure was the method of choice, followed by surgical ligation. Birthweight <1000 g and first cycle of pharmacologic treatment failure were associated with higher mortality.
RESUMO Objetivo: Caraterizar o número e métodos de fechamento de canal arterial durante 16 anos numa maternidade de nível terciário. Métodos: Estudo retrospetivo de nascidos entre 01 de janeiro de 2003 a 31 de dezembro de 2018 submetidos a fechamento do canal arterial por métodos farmacológico, cirúrgico e/ou percutâneo. Avaliaram-se idade gestacional, sexo, peso ao nascimento, número de fechamentos por ano e método utilizado. Aferiram-se as taxas de sucesso de método farmacológico e de mortalidade e sua associação com peso ao nascer, fármaco utilizado e insucesso do fechamento. Resultados: Verificaram-se 47.198 recém-nascidos, 5.156 prematuros, dos quais 325 com canal arterial patente, sendo 106 com indicação para fechamento (idade gestacional mediana 27 semanas, peso <1000 g em 61%). Verificou-se diminuição do número de fechamentos ao longo dos anos, sobretudo a partir de 2010. O fechamento ocorreu em 62% após primeiro ciclo de tratamento farmacológico e em 74% após segundo. Após insucesso farmacológico, 12 realizaram ligadura cirúrgica e dois, fechamento percutâneo. Houve indicação de ligadura cirúrgica exclusiva em quatro. O ibuprofeno substituiu a indometacina em 2010. O acetaminofen foi usado em três doentes. A mortalidade nos 106 pacientes foi de 12%, associando-se ao peso ao nascer (13/65 <1000 vs. 0/41 >1000 g; p=0,002) e à falha do primeiro ciclo de tratamento farmacológico (13/27 com falha vs. 0/75 com sucesso; p<0,001). Conclusões: Consenso nacional de 2010 para diagnóstico e tratamento do canal arterial nos prematuros levou à diminuição do número de fechamentos desse canal. O fechamento farmacológico foi o método mais utilizado, seguido da ligadura cirúrgica. Peso <1000 g e falha no primeiro ciclo de fechamento farmacológico se associaram à maior mortalidade.
Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Premature Birth/epidemiology , Ductus Arteriosus, Patent/epidemiology , Ibuprofen/therapeutic use , Indomethacin/therapeutic use , Retrospective Studies , Gestational Age , Infant, Very Low Birth Weight , Ductus Arteriosus, Patent/surgery , Ductus Arteriosus, Patent/drug therapy , Infant, Extremely Premature , Tertiary Care Centers/statistics & numerical data , Acetaminophen/therapeutic use摘要
Se presentan dos casos clínicos y la revisión de la literatura actual sobre luxación convergente de codo. En el primer caso, se muestra cómo un retraso en el diagnóstico conducirá a una reducción abierta y fijación con agujas de Kirschner, mientras que un diagnóstico temprano permite la reducción cerrada y el tratamiento conservador como se describe en el segundo caso. La clave de diagnóstico para la luxación convergente de codo radica en la correcta interpretación de las radiografías y el bloque de prono-supinación en el examen físico. Se recomienda el uso de indometacina para evitar calcificaciones heterotópicas. El resultado final es mejor cuando el diagnóstico es precoz, independientemente del método de reducción. Nivel de Evidencia: IV
We describe two clinical cases and review the available literature on convergent elbow dislocation. Our first case shows how a delay in the diagnosis will lead to an open reduction and internal fixation with K-wires. On the other hand, an early diagnosis prompts a closed reduction without fixation as it is described in the second case. The diagnostic key for the convergent dislocation of the elbow lies in the correct interpretation of radiographs and the prono-supination block on physical examination. The use of indomethacin is recommended to avoid heterotopic calcifications. The final outcome is better when an early diagnosis is achieved regardless of the reduction method. Level of Evidence: IV
Subject(s)
Child , Indomethacin/therapeutic use , Joint Dislocations/surgery , Joint Dislocations/diagnosis , Joint Dislocations/therapy , Elbow Joint/injuriesSubject(s)
Humans , Male , Female , Middle Aged , Aged , Prednisolone/administration & dosage , Gout/drug therapy , Anti-Inflammatory Agents/administration & dosage , Pain/etiology , Pain/prevention & control , Prednisolone/adverse effects , Indomethacin/therapeutic use , Double-Blind Method , Administration, Oral , Multicenter Studies as Topic , Adrenal Cortex Hormones/administration & dosage , Adrenal Cortex Hormones/adverse effects , Emergency Service, Hospital , Pragmatic Clinical Trials as Topic , Gout/physiopathology , Hong Kong , Anti-Inflammatory Agents/adverse effects摘要
Abstract: Eosinophilic pustular folliculitis (EPF) or Ofuji disease is a rare dermatosis, prone to recurrence and chronicity. The peak incidence occurs in the third decade of life and its exact etiology remains unknown. Evidence suggests that the expression of adhesion molecules and the production of cytokines activate the follicular unit, but the stimulus that triggers these changes remains unclear. The three clinical variants reported in the literature include classic EPF, immunosuppression-associated EPF, and infancy-associated EPF. We report a case of eosinophilic pustular folliculitis with peculiar epidemiological characteristics, which represents a challenging therapeutic scenario.
Subject(s)
Humans , Female , Adult , Pregnancy Complications , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Indomethacin/therapeutic use , Skin Diseases, Vesiculobullous/drug therapy , Eosinophilia/drug therapy , Folliculitis/drug therapy , Recurrence , Pregnancy , Skin Diseases, Vesiculobullous/complications , Skin Diseases, Vesiculobullous/pathology , Eosinophilia/complications , Eosinophilia/pathology , Folliculitis/complications , Folliculitis/pathology , Granulocytes/pathology摘要
PURPOSE: To evaluate the anti-inflammatory and analgesic effects of green tea (Camellia sinensis) in mice. METHODS: The anti-inflammatory effect of alcoholic extracts of green tea (AE) was evaluated in a cell migration assay with four groups of six Swiss mice receiving 0.07g/Kg or 0.14g/Kg EA (treatment groups), saline (negative control) or 10mg/Kg indomethacin (positive control) by gavage. One hour later 300 µg carrageen an was administered intraperitoneally or subcutaneously. The analgesic effect was evaluated using four groups of six animals receiving 0.07g/Kg or 0.14g/Kg EA, saline or 10mg/Kg indomethacin subcutaneously, followed 30 minutes later by 1% acetic acid. RESULTS: When administered subcutaneously at either dose (0.07g/Kg and 0.14g/Kg), AE inhibited carrageenan-induced cell migration (p<0.05). However, when administered by gavage, only the latter (0.14 g/Kg) was efficient (p<0.05). AE at both doses (0.07g/Kg and 0.14g/Kg) inhibited abdominal contortions (p<0.05), but the effect was not dose-dependent. CONCLUSION: Green tea was shown to have analgesic and anti-inflammatory properties and may constitute a natural treatment option in chronic inflammatory disorders. .
Subject(s)
Animals , Male , Mice , Analgesics/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Camellia sinensis/chemistry , Phytotherapy/methods , Plant Extracts/therapeutic use , Tea/chemistry , Cell Migration Assays , Catechin/therapeutic use , Infusions, Subcutaneous , Indomethacin/therapeutic use , Inflammation/drug therapy , Reproducibility of Results , Time Factors , Treatment Outcome摘要
Objective: To describe the results of a long-term follow-up of Bartter syndrome patients treated with different drugs. Method: Patients were diagnosed according to clinical and laboratory data. Treatment protocol was potassium supplementation, sodium, spironolactone, and non-steroidal anti-inflammatory drug. Patients who developed proteinuria were converted to angiotensin conversion enzyme inhibitor. The variables evaluated for each drug were Z-score for weight and stature, proteinuria, creatinine clearance, gastrointestinal complaints, amount of potassium supplementation, serum potassium and bicarbonate levels, and findings of upper digestive endoscopy. Results: 20 patients were included. Follow-up was 10.1 ± 5.2 years. 17 patients received indomethacin for 5.9 ± 5.3 years; 19 received celecoxib, median of 35 months; and five received enalapril, median of 23 months. During indomethacin, a statistically significant increase was observed in the Z-score for stature and weight, without a change in the creatinine clearance. Seven of 17 patients had gastrointestinal symptoms, and upper digestive endoscopy evidenced gastritis in three patients and gastric ulcer in four patients. During celecoxib use, a significant increase was detected in the Z-score for stature and weight and a reduction of hyperfiltration; seven patients presented gastrointestinal symptoms, and upper digestive endoscopy evidenced mild gastritis in three. During enalapril use, no significant changes were observed in the Z-score for stature, weight and creatinine clearance. The conversion to enalapril resulted in a significant reduction in proteinuria. Conclusion: The authors suggest starting the treatment with celecoxib, and replacing by ACEi if necessary, monitoring the renal function. The safety and efficacy of celecoxib need to be assessed in larger controlled studies. .
Objetivo: Descrever os resultados de um acompanhamento de longo prazo de pacientes com síndrome de Bartter tratados com diferentes medicamentos. Método: Pacientes diagnosticados segundo os dados clínicos e laboratoriais. Protocolo de tratamento: suplementação de potássio, sódio, espironolactona e medicamento anti-inflamatório não esteroidal. Os pacientes que desenvolveram proteinúria foram submetidos a inibidor da enzima de conversão da angiotensina. As variáveis avaliadas durante o uso de cada medicamento foram: escore Z para peso e estatura, proteinúria, depuração da creatinina, queixas gastrointestinais, quantidade da suplementação de potássio, níveis séricos de potássio e bicarbonato e achados da endoscopia digestiva alta. Resultados: Foram incluídos 20 pacientes. O acompanhamento foi de 10,1 ± 5,2 anos. No total, 17 pacientes receberam indometacina por 5,9 ± 5,3 anos, 19 receberam celecoxib por aproximadamente 35 meses e cinco receberam enalapril por aproximadamente 23 meses. Durante o uso de indometacina, observamos um aumento estatístico significativo no escore Z para estatura e peso, sem alteração na depuração da creatinina. 7/17 pacientes apresentaram sintomas gastrointestinais, e a endoscopia digestiva alta mostrou gastrite em três pacientes e úlcera gástrica em quatro. Durante o uso de celecoxib, detectamos um aumento significativo no escore Z para estatura e peso e uma redução da hiperfiltração; sete pacientes apresentaram sintomas gastrointestinais e a endoscopia digestiva alta mostrou gastrite leve em três pacientes. Durante o uso de enalapril, não observamos alterações significativas no escore Z para estatura, peso e depuração da creatinina. A mudança da medicação para enalapril resultou em uma ...
Subject(s)
Female , Humans , Infant , Male , Bartter Syndrome/drug therapy , Cyclooxygenase Inhibitors/therapeutic use , Enalapril/therapeutic use , Indomethacin/therapeutic use , Pyrazoles/therapeutic use , Sulfonamides/therapeutic use , Bartter Syndrome/complications , Bicarbonates/blood , Body Height/drug effects , Body Weight/drug effects , Creatinine/analysis , Follow-Up Studies , Potassium/blood , Proteinuria/drug therapy , Proteinuria/etiology , Retrospective Studies , Time Factors , Treatment Outcome摘要
BACKGROUND: The current study aims at evaluating the analgesic, anti-pyretic and anti-inflammatory properties of methanolic extract of the stem, bark and leaves of Launaea sarmentosa and Aegialitis rotundifolia roxb. RESULTS: The AELS and AEAR extract presented a significant (***p < 0.001) dose dependent increase in reaction time in writhing method and showed inhibition of 63.1% and 57.1% respectively at the doses of 400 mg/kg body weight while standard drug showed (P < 0.001) inhibition of 69.23%. In tail immersion method, AELS and AEAR showed maximum time of tail retention at 30 min in hot water i.e. 6.93 sec and 6.54 sec respectively at highest doses of 400 mg/kg body weight than lower dose while standard pentazocine showed reaction time of 7.62 sec. The AELS and AEAR extract also exhibited promising anti-inflammatory effect as demonstrated by statistically significant inhibition of paw volume by 32.48% and 26.75% respectively at the dose of 400 mg/kg body weight while the value at the dose of 200 mg/kg body weight were linear to higher dose at the 3rd hour of study. On the other hand, Standard indomethacin inhibited 40.13% of inflammation (***P < 0.001). In Cotton-pellet granuloma method, AELS and AEAR extract at the dose of 400 mg/kg body weight exhibited inhibition of inflammation of 34.7% and 29.1% respectively while standard drug showed (P < 0.001) inhibition of 63.22%. Intraperitoneal administration of AELS and AEAR showed dose dependent decrease in body temperature in brewer's yeast induced hyperthermia in rats at both doses. However, AELS significantly decreased body temperature (***p < 0.001) at 400 mg/kg compared to control. CONCLUSIONS: Present work propose that the methanolic extract of Launaea sarmentosa and Aegialitis rotundifolia roxb possesses dose dependent pharmacological action which supports its therapeutic use in folk medicine possibly mediated through the inhibition or blocking of release of prostaglandin and/or actions of vasoactive substances such as histamine, serotonin and kinins.
Subject(s)
Animals , Male , Female , Mice , Rats , Asteraceae/chemistry , Plumbaginaceae/chemistry , Antipyretics/therapeutic use , Fever/drug therapy , Pain Management , Phytotherapy , Time Factors , Bangladesh , Plant Extracts/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Aspirin/therapeutic use , Indomethacin/therapeutic use , Rats, Wistar , Plant Leaves/drug effects , Plant Leaves/metabolism , Toxicity Tests, Acute , Edema/chemically induced , Edema/drug therapy , Analgesics/therapeutic use , Inflammation/drug therapy摘要
BACKGROUND: Algesia and inflammation are related with several pathological conditions. It is known that many drugs available for the treatment of these problems cause unwanted side effects. This study was aimed at evaluating acute toxicity and anti-inflammatory activity of Lampaya medicinalis Phil. (Verbenaceae) widely used in the folk medicine of Northern Chile against rheumatism, arthritis and body joints pain. RESULTS: Oral administration of hydroalcoholic extract (HAE) at the highest dose of 3000 mg/ Kg body weight resulted in no mortalities or evidence of significant behavioral changes. Histological examination revealed normal architecture and no significant adverse effects were observed on the liver, kidney, heart, lung or ovaries and testicles. The results suggest that the oral administration of hydroalcoholic extract (HAE) from Lampaya medicinalis did not produce any toxic effect in rats. Hydroalcoholic extract (HAE) significantly inhibited the carrageenan-induced rat paw edema in dose - response relationship, at test doses of 37.5, 75, 150 and 300 mg/Kg body weight. Maximum inhibition (61.98 ± 2.69%) was noted at 300 mg/Kg after 2 h of drug treatment carrageenan induced paw edema, whereas indomethacin produced 47.90 ± 1.16% of inhibition. The inhibitory values of edema at 3 h postcarrageenan were 31.04±0.75%, 40.51 ± 2.36%, 48.97 ± 1.14% and 56.87 ± 0.41% for 37.5, 75, 150, and 300 mg/kg of extract respectively. Indomethacin (10 mg/Kg) gave a percentage inhibition of 49.44 ± 1.44. HAE (300 and 150 mg/kg) induced an anti-inflammatory effect greater than (or comparable) with the effect of indomethacin from 2nd to 4th hours of the experiment. CONCLUSIONS: Our results reveal for first time that compounds contained in the hydroalcoholic extract ofLampaya medicinalis Phil exert anti-inflammatory effect and the oral administration is safe and non toxic up to dose level 3000 mg/kg body weight. The anti-inflammatory activity may be associated with the presence of flavonoids. These findings also justify the traditional use of the plant for treating pain.
Subject(s)
Animals , Female , Male , Anti-Inflammatory Agents/toxicity , Edema/drug therapy , Inflammation/drug therapy , Plant Extracts/toxicity , Verbenaceae , Administration, Oral , Alanine Transaminase/blood , Anti-Inflammatory Agents/isolation & purification , Aspartate Aminotransferases/blood , Chile , Carrageenan/administration & dosage , Heart/drug effects , Hindlimb/injuries , Indomethacin/therapeutic use , Kidney/drug effects , Liquid-Liquid Extraction , Liver/drug effects , Lung/drug effects , Medicine, Traditional , Myocardium , Ovary/drug effects , Plant Extracts/chemistry , Plant Leaves/chemistry , Rats, Sprague-Dawley , Testis/drug effects , Toxicity Tests, Acute/methodsSubject(s)
Humans , Adult , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Indomethacin/therapeutic use , Pancreatitis/prevention & control , Cholangiopancreatography, Endoscopic Retrograde/adverse effects , Administration, Rectal , Double-Blind Method , Length of Stay , Patient Selection , Pancreatitis/etiology , Risk Factors , Suppositories摘要
JUSTIFICATIVA E OBJETIVOS: A Hemicrania Contínua (HC) é uma cefaleia primária, incapacitante, caracterizada por dor contínua, unilateral e responsiva à indometacina. Existem sintomas comuns às cefaleias trigêmino-autonômicas e à migrânea, que dificultam o diagnóstico. A presente revisão busca descrever a HC em uma série de casos e analisar as melhores evidências disponíveis sobre alternativas terapêuticas. MÉTODOS: Revisão sistemática dos prontuários e dos diários de dor de 1.600 pacientes, atendidos entre janeiro de 1992 e janeiro de 2011 em um ambulatório de cefaleia. RESULTADOS: Dez pacientes com possível diagnóstico de Hemicrania Contínua foram selecionados; sete receberam diagnóstico de HC segundo a II Classificação Internacional das Cefaleias. Nenhum paciente havia recebido o diagnóstico correto antes de ser atendido no ambulatório e o tempo médio para o mesmo foi de 12 anos. A amitriptilina foi eficaz no tratamento profilático de 66,6 por cento dos casos, a gabapentina em 20 por cento e o topiramato em 10 por cento. CONCLUSÕES: A HC deve ser considerada entre as hipóteses diagnósticas de pacientes com cefaleia contínua, sem alterações ao exame neurológico e exames subsidiários, independentemente da idade do surgimento. O tratamento usual, 100 mg a 150 mg diários de indometacina, possui riscos relevantes associados ao uso a curto e longo prazos e pode não ser boa escolha para uso contínuo. Estudos recentes apontam possíveis alternativas: gabapentina, topiramato, inibidores da ciclooxigenase-2, piroxican betaciclodextrina, amitriptilina e melatonina. Outras drogas foram descritas como eficazes em relatos isolados, mas a maioria foi considerada ineficaz em outros casos de HC.
BACKGROUND AND OBJECTIVES: Hemicrania Continua (HC) is a primary, disabling headache characterized by a continuous unilateral pain and responsive to indomethacin. There are symptoms common to the trigeminal-autonomic cephalalgias and migraine that complicate the diagnosis. This review aims to describe HC in a case series and review the best available evidence on alternative therapies. METHOD: A systematic review of medical records and diaries of pain of 1,600 patients treated between January 1992 and January 2011 in a headache outpatient clinic. RESULTS: Ten patients with a possible diagnosis of hemicrania continua were selected; seven were diagnosed with HC according to the II International Classification of Headache Disorders. None of the patients had received the correct diagnosis before being treated at the outpatient clinic and the average time for treatment was 12 years. Prophylactic treatment was effective in 66.6 percent of cases with amitriptyline, 20 percent with gabapentin and 10 percent with topiramate. CONCLUSIONS: HC should be considered among the diagnostic hypotheses of patients with continuous headache, with no change in neurological examination and additional tests, regardless the age of onset. The standard treatment with indomethacin (100-150 mg.day-1) has significant risks associated with both short and long term use and may not be a good choice for continuous use. Recent studies point out possible alternatives: gabapentin, topiramate, cyclooxygenase-2 inhibitors, piroxicam, beta-cyclodextrin, amitriptyline, melatonin. Other drugs were described in different reports as efficient, but most of them were considered inefficient in other HC cases.
JUSTIFICATIVA Y OBJETIVOS: La Hemicránea Continua (HC) es una cefalea primaria, invalidante, caracterizada por un dolor continuo, unilateral y que responde a la indometacina. Existen síntomas comunes a las cefaleas trigémino-autonómicas y a la migraña, que dificultan el diagnóstico. La presente revisión pretende describir la HC en una serie de casos, y analizar las mejores evidencias disponibles sobre las alternativas terapéuticas. MÉTODO: Revisión sistemática de las historias clínicas y de los reportes diarios de dolor de 1.600 pacientes, atendidos entre enero de 1992 y enero de 2011, en un ambulatorio de cefalea. RESULTADOS: Diez pacientes con un posible diagnóstico de Hemicránea Continua fueron seleccionados; siete recibieron diagnóstico de HC según la II Clasificación Internacional de las Cefaleas. Ningún paciente había recibido el diagnóstico correcto antes de ser atendido en el ambulatorio y el tiempo promedio para el mismo fue de 12 años. La amitriptilina fue eficaz en el tratamiento profiláctico de 66,6 por ciento de los casos, la gabapentina en 20 por ciento y el topiramato en un 10 por ciento. CONCLUSIONES: La HC debe ser considerada entre las hipótesis diagnósticas de pacientes con cefalea continua, sin alteraciones al examen neurológico y exámenes posteriores, independientemente de la edad de su surgimiento. El tratamiento usual, 100 mg a 150 mg diarios de indometacina, conlleva a riesgos relevantes asociados con el uso a corto y largo plazo, y puede que no sea una buena elección para el uso continuo. Estudios recientes indican como posibles alternativas: gabapentina, topiramato, inhibidores de la ciclooxigenasa-2, piroxican betaciclodextrina, amitriptilina y melatonina. Otros fármacos fueron descritos como eficaces en relatos aislados, pero la mayoría fue considerada ineficaz en otros casos de HC.
Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Headache/drug therapy , Indomethacin/therapeutic use摘要
JUSTIFICATIVA E OBJETIVOS: O objetivo deste estudo foi rever na literatura pertinente aos seguintes tópicos: fisiopatologia,quadro clínico, tratamento e profilaxia mais indicados para pacientes com febre reumática, de modo que os profissionais médicos possam diagnosticar mais precocemente esta doença e tratá-la corretamente, visando o maior bem-estar dos pacientes.CONTEÚDO: Utilizou-se como fonte de base de pesquisa as bases de dados da LILACS, Scielo e Medline, bem como periódicos nacionais e internacionais abordando assuntos relacionados ao tema, como os da Revista Brasileira de Reumatologia, Jornal de Pediatria, Revista da Sociedade Brasileira de Cardiologia de São Paulo, entre outros.CONCLUSÃO: A febre reumática é uma doença que pode evoluir com complicações graves, mas que pode ser facilmente prevenida,contudo o percentual de pacientes acometidos ainda é crescente.A deficiência de conhecimento do profissional de saúde em relação ao manuseio clínico dessa doença contribui para que a FR seja um problema de saúde pública. Assim, há uma forte necessidade de promover ações em medicina preventiva eficazes para a população.(AU)
BACKGROUND AND OBJECTIVES: To present an updatedr eview of the literature pertaining to the following topics: pathophysiology,clinical features, treatment and prophylaxis indicated for most patients with rheumatic fever, so that health professionals able to diagnose this disease early and treat it correctly, aimedat improving the well-being of patients.CONTENTS: It was used as a source of basic research in the databases LILACS, Scielo and Medline, as well as national and international journals addressing issues related to the topic, such asthe Journal of Rheumatology, Journal of Pediatrics, and Journal of the Brazilian Society of Cardiology Sao Paulo, among others.CONCLUSION: Rheumatic fever is a disease that can develop serious complications, but can be easily prevented, yet the percentage of patients affected by the disease is still growing. Deficiencyof knowledge of the health professional in relation to the clinical management of this pathology contributes to the FR is a public health problem. Thus there is a strong need to promote actions in preventive medicine effective for the population.(AU)
Subject(s)
Humans , Rheumatic Fever/physiopathology , Rheumatic Fever/drug therapy , Rheumatic Heart Disease , Thoracic Surgery/instrumentation , Methylprednisolone/therapeutic use , Prednisone/therapeutic use , Echocardiography/instrumentation , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Aspirin/therapeutic use , Dipyrone/therapeutic use , Indomethacin/therapeutic use , Naproxen/therapeutic use , Stethoscopes , Acetaminophen/therapeutic use摘要
Non-steroidal anti-inflammatory drugs (NSAIDS) are the first line of therapy in acute gouty arthritis. NSAIDs inhibit the cyclooxygenase pathway, but not the lipooxygenase activity and can have many adverse effects and thus have a limited effect on the control of inflammation in this disease. In this work we studied the effect of montelukast on the cellular inflammatory infiltrate in a model of murine arthritis induced by sodium monourate crystals (SMU), using a subcutaneous air cavity (air pouch) in BALB/c mice. Seven groups of BALB/c mice (n = 4) were distributed into five experimental groups and two inflammatory control groups, a positive and a negative one. Previous to SMU exposure, the experimental groups received montelukast (1 and 0.01 mg/Kg/w) and/or indomethacine (2.5 mg/Kg/w), followed by administration of SMU in the air pouch. The total and differential counts of inflammatory cells were analyzed after 2, 6, 12 and 24 hours. Montelukast, significantly reduced the total number of cells (p<0.05), with a predominant impact on polymorphonuclear over mononuclear cells, especially after 12 hours of the medication. The montelukast/indometacine combination showed an additive effect. Our data show that montelukast has an anti-inflammatory effect in the model of gouty arthritis. Consequently, anti-leukotrienes could represent a new and effective therapy, either isolated or combined with conventional therapy of gouty arthritis.
En artritis gotosa aguda las drogas antiinflamatorias no esteroideas son la primera línea terapéutica. Este tratamiento no es satisfactorio porque inhibe la ciclooxigenasa sin modificar la actividad de la lipooxigenasa, y puede acompañarse de numerosos efectos adversos. Investigamos el efecto de montelukast sobre el infiltrado celular inflamatorio en un modelo de artritis múrida inducida por cristales de monourato de sodio (MUS) en el modelo experimental de la bolsa de aire (air pouch). Siete grupos de ratones BALB/c (n = 4) fueron distribuidos en cinco grupos experimentales y dos grupos controles inflamatorios: positivo y negativo. Los grupos experimentales recibieron, montelukast (1 y 0,01 mg/Kg/p) y/o indometacina (2,5 mg/Kg/p) por vía oral, previo a la administración de MUS en la bolsa del aire. El conteo absoluto y diferencial de las células inflamatorias fue analizado después de 2, 6, 12 y 24 horas de tratamiento. El tratamiento con montelukast redujo significativamente el número total de células presentes en el infiltrado inflamatorio (p < 0,05), con un efecto mayor sobre polimorfonucleares que sobre las células mononucleares, y con un máximo efecto a las 12 horas después de la administración del medicamento. La combinación montelukast/indometacina mostró un efecto aditivo. Los resultados demuestran que montelukast tiene un efecto antiinflamatorio en el modelo de la artritis gotosa. Por lo tanto, los anti-leucotrienos podrían representar una nueva y eficaz terapia, aislada o en combinación con la terapéutica convencional, para la artritis gotosa.
Subject(s)
Animals , Male , Mice , Acetates/therapeutic use , Arthritis, Gouty/drug therapy , Leukotriene Antagonists/therapeutic use , Quinolines/therapeutic use , Uric Acid/toxicity , Acetates/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Arthritis, Gouty/chemically induced , Arthritis, Gouty/prevention & control , Cell Migration Assays, Leukocyte , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Drug Synergism , Indomethacin/administration & dosage , Indomethacin/therapeutic use , Inflammation/chemically induced , Inflammation/drug therapy , Leukocytes, Mononuclear/drug effects , Leukotriene Antagonists/administration & dosage , Mice, Inbred BALB C , Neutrophils/drug effects , Premedication , Quinolines/administration & dosage摘要
Although the prophylactic administration of indomethacin in extremely low-birth weight infants reduces the frequency of patent ductus arteriosus and severe intraventricular hemorrhage, it does not appear to provide any long-term benefit in terms of survival without neurosensory and cognitive outcomes. Considering the increased drug-induced reduction in renal, intestinal, and cerebral blood flow, the use of prophylaxis cannot be routinely recommended in preterm neonates. However, a better understanding of the genetic background of each infant may allow for individualized prophylaxis using NSAIDs and metabolomics.
Subject(s)
Humans , Infant, Newborn , Cyclooxygenase Inhibitors/therapeutic use , Ductus Arteriosus, Patent/prevention & control , Ibuprofen/therapeutic use , Indomethacin/therapeutic use , Infant, Premature, Diseases/prevention & control , Infant, Extremely Low Birth Weight , Intracranial Hemorrhages/prevention & control , Ligation摘要
La hemicránea paroxística es un cuadro de cefalea primaria, agrupada dentro de las Cefaleas Trigémino Autonómicas(CTAs), junto con la cefalea cluster y el SUNCT, caracterizada por la presencia de dolor unilateral en la distribución somática del nervio trigeminal y asociada a características autonómicas craneofaciales ipsilaterales. A pesar de sus elementos comunes, de forma individual, difieren con respecto a su duración, frecuencia y la respuesta a indometacina. Se presenta un caso de hemicránea paroxística de localización primaria dentomaxilar, sus características comunes y particulares respecto de las demás CTAs, y la necesidad del diagnóstico diferencial con cuadros dolorosos provenientes de estructuras estomatognáticas.
Paroxysmal hemialgia is a primary cephalea of the AutonomousTrigeminus Cephaleas type (ATCs) along with cluster cephalea and SUNCT characterized by the presence of unilateral pain in the somatic distribution of the trigeminal nerve associated to autonomous craniofacial ipsilateral characteristics. Despite the common elements, individually they differ with respect to the length, frequency and response to indomethacin. We present a primary location dento maxilar paroxysmal hemialgia case, its common and particular characteristics with respect to all other ATCs and the need to a differential diagnose with pain coming from stomatognathic structures.
Subject(s)
Humans , Adult , Female , Facial Pain/diagnosis , Facial Pain/drug therapy , Paroxysmal Hemicrania/diagnosis , Paroxysmal Hemicrania/drug therapy , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Indomethacin/therapeutic use , Trigeminal Autonomic Cephalalgias摘要
BACKGROUND AND OBJECTIVES: Stimulations with formalin in the orofacial region can be related to transient or subacute nociceptive activity and behavioral changes. The evaluation of behavioral changes induced by persistent or chronic irritating nociceptive substance has not yet been described.METHOD: Complete Freund's Adjuvant (CFA) was injected in the temporomandibular joint (TMJ) region of rats and analyzed comparing it to the groups treated with saline and 2.5% formalin. In addition, behaviors such as grooming, freezing, rest/sleeping and chewing-like were electronically observed and quantified.RESULTS: It was shown that the chewing-like behavior was significantly increased and that it was inhibited by indometacin (5 mg/kg) and morphine (4 mg/kg). CONCLUSION: These results suggest that chewing-like may be a possible behavior of persistent or chronic orofacial pain, and may be a tool for clinical-pharmacological studies.
JUSTIFICATIVA E OBJETIVOS: Estímulos com formalina na região orofacial podem estar relacionados com a atividade nociceptiva e as alterações comportamentais transitórias ou subagudas. A avaliação de comportamentos sob ação de substância irritante nociceptiva persistente e crônica ainda não foi descrita.MÉTODO: Foi feita injeção de adjuvante completo de Freund (ACF) na região da articulação temporomandibular (ATM) de ratos e foi analisada comparando-a com os grupos tratados com salina e formalina a 2,5%. Além disso, foram observados e quantificados eletronicamente os comportamentos grooming, freezing, rest/sleeping e chewing-like (mastigação). RESULTADOS: Observou-se que o comportamento mastigação (chewing-like) estava significativamente aumentado e que ele foi inibido pela indometacina (5 mg/kg) e morfina (4 mg/kg).CONCLUSÃO: Esses resultados sugerem ser o chewing-like um possível comportamento de dor orofacial persistente, oferecendo-se como instrumento para análise clínico-farmacológica
Subject(s)
Animals , Male , Rats , Analgesics/pharmacology , Facial Pain/physiopathology , Mastication/drug effects , Temporomandibular Joint Disorders/physiopathology , Analgesics, Opioid/therapeutic use , Anesthetics, Local/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Behavior, Animal , Disease Models, Animal , Freund's Adjuvant , Indomethacin/therapeutic use , Lidocaine/therapeutic use , Morphine/therapeutic use , Rats, Wistar , Temporomandibular Joint Disorders/chemically induced摘要
BACKGROUND: Patients undergoing intrasound therapy are often concurrently on NSAIDs. The effect of varied intensities of intrasound therapy with NSAIDs on tendon healing is yet to be determined. OBJECTIVE: The study investigated the effects of a concurrent admistration of low and high intensity intrasound therapy (LIRTetHIRT) with indomethacin (Indocid) on the morphology of the tendon in the early stage of healing. METHODS: Thirty five male rats were divided randomly into seven groups; groups 2-6 underwent an induced crush injury. Group 1; nil injury and nil treatment. Group 2: injury but nil treatment. Group 3: Indomethacin only. Group 4: LIRT only; Group 5: Indocidand LIRT; Group 6: HIRT; Group 7: Indocid and HIRT. Intrasound therapy (IRT) commenced 24 hours post-injury and was given alternate days for the first 10 days post injury. Indocid was given at a dosage of 0.4 mg/kg body weight daily. On the 11 day post injury; the animals were sacrificed and the tendons excised and processed for histological study. RESULTS: Indocid significantly (p 0.05) reduced the tenocyte population when combined with LIRT but marginally increased it when combined with HIRT (p 0.05). There was significant difference in the tenocyte population between the combined Indocid and LIRT and the combined Indocid and HIRT groups (p 0.05). CONCLUSION: High intensity intrasound given concurrently with oral indomethacin resulted in tenoblast proliferation and promoted healing in the injured tendon
Subject(s)
Indomethacin/administration & dosage , Indomethacin/therapeutic use , Tendons摘要
A avaliação das tecnologias neonatais assume grande importância em face dapredominância atual do componente neonatal na mortalidade infantil e da necessidade de melhor avaliação dos recursos tecnológicos utilizados na assistência a essa faixa etária. Oestudo teve por objetivo examinar as evidências acerca do uso profilático dosantiinflamatórios não-esteróides indometacina e ibuprofeno - no fechamento do canal arterial em recém-nascidos prematuros, por intermédio de uma revisão sistemática. Foi executada busca nas bases de referências bibliográficas MEDLINE, Web of Science, Scopus e LILACS, além dos registros da Colaboração Cochrane e da International Network of Agencies for Health Technology Assessment (INAHTA). Foram encontradas 226 citações, dos quais 93 foram para avaliação de resumos. Destes, foram excluídos 68 trabalhos por não preencherem os critérios estabelecidos de inclusão e qualidade, restando 25 artigos para a revisão sistemática, sendo seis envolvendo o uso de ibuprofeno e 19, o de indometacina. O fechamento farmacológico do canal arterial, eleito como desfecho primário,esteve presente em todos os trabalhos incluídos. Outros desfechos estudados foram: fechamento cirúrgico do canal arterial, mortalidade neonatal, doença da membrana hialina, hemorragia intracraniana, sepse neonatal, enterocolite necrosante, tempo de ventilação mecânica invasiva, tempo de oxigenioterapia, tempo de internação hospitalar, pneumotórax, hemorragia pulmonar, hemorragia gastrointestinal, distúrbio de coagulação, creatinina,oligúria, retinopatia da prematuridade, broncodisplasia pulmonar e alterações neurológicas aos 36 meses...